(688670)"JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 688670 · · 10 pages · Chinese
Summary by 6ix AI
The report highlights significant risks to the company's revenue due to changes in flu vaccine recommendations by health authorities, impacting product sales. It indicates that the company may not achieve its revenue targets for the year, potentially leading to financial delisting risks. The report also includes a disclaimer regarding the accuracy and completeness of the information provided by the board of directors.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu gdk Biotechnology Co., Ltd. on 6ix
Earlier from Jiangsu gdk Biotechnology
- (688670)"JIANGSU GDK BIOLOGICAL TECHNOLOGY CO., LTD."Announcement on Risk Warning Regarding the Receipt of a Drug Registration Certificate for the Company's Split Virion Influenza Vaccine and Uncertainty in Operating Performance
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026
- Announcement on Renewal of Joint Control and Concerted Action Agreement by Controlling Shareholder and Joint Actual Controllers
- Announcement on Reply to Regulatory Inquiry Letter Regarding Information Disclosure of 2025 Annual Report
Follow Jiangsu gdk Biotechnology into a list and get an email when it puts out news.
Follow Jiangsu gdk Biotechnology